AI and biotech pioneer Alex Zhavoronkov commits his life and estate to longevity for all

Zhavoronkov's "Longevity Pledge" invites the world's 1% and longevity enthusiasts to make longer, healthier human lifespans a reality for everyone.

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Zhavoronkov’s “Longevity Pledge” invites the world’s 1% and longevity enthusiasts to make longer, healthier human lifespans a reality for everyone.

Yesterday, the AI, biotech and longevity pioneer Alex Zhavoronkov publicly called for the world’s most successful founders, altruistic billionaires and dedicated longevity pioneers to join him in his unorthodox and principled Longevity Pledge.

Longevity.Technology: Alex Zhavoronkov, PhD, is the founder and Chief Longevity Officer of Deep Longevity, the founder and CEO of Insilico Medicine, and an adjunct professor at the esteemed Buck Institute for Research on Aging. He serves on the Visionary Board of the Longevity Science Foundation, is part of the advisory board for longevity and biotech venture capital firm LongeVC and advises multiple other non-profits and startups working in longevity biotechnology. In a nutshell, when it comes to longevity, Zhavoronkov knows his onions.

Yesterday, Alex Zhavoronkov formally announced his personal Longevity Pledge, which means he commits his wealth and resources, as well as all of his remaining time to supporting and developing research and clinical solutions for extending healthy productive longevity for everyone on the planet.

READ MORE: Insilico’s Alex Zhavoronkov announces Longevity Pledge

“Making productive longevity, or the ability to live a longer, healthier life, is the most altruistic cause you can support,” said Zhavoronkov. “If we could extend everyone’s life by just one more high-quality, healthy year, our world would benefit from roughly 8 billion more impactful years in a few generations. These years could mean thousands of new medical and scientific discoveries, impactful action on climate change, and more. This is no time to waste. I hope my example will motivate people with similar backgrounds to not only commit their wealth, but also their intellect, skills, and ingenuity to this strangely underappreciated cause.”

Alex Zhavoronkov’s personal Longevity Pledge includes:

  • Committing his entire fortune (including future earnings) to the cause of human longevity
  • 100% of his time to advising, founding, creating and pursuing longevity initiatives
  • Invest solely in companies with the potential to extend healthy, productive life, forming a global longevity ecosystem. These companies can grow, become sustainable, give rise to other companies, and return profits that can be reinvested in other longevity enterprises.

The full pledge can be read here.

By inviting others to join the Longevity Pledge, Alex Zhavoronkov believes that four significant breakthroughs for human longevity will be accelerated from approaching release in 20+ years to broadly available in 5 years:

  • The development of AI-powered drug discovery platforms that will significantly derisk, accelerate, and democratise the discovery of novel therapeutics. The cost of drug discovery and development may exceed $3 billion to launch just one novel drug on the market. According to Insilico, the process from disease hypothesis and target discovery to launch of the drug in the clinic can take at least 12 years and fails 99% of the time.
  • Personalised medicine, treatment and drugs: develop fully automated systems that can customise care to each patient and help discover novel therapeutics and therapeutic combinations for individuals.
  • Cryotherapy/cryobiology and biostasis: recent advances can allow doctors to freeze and unfreeze organs rapidly, and possibly entire bodies, to enable long-term storage, transport, and even “biostasis” for the terminally ill or irreparably frail.
  • AI and robotics-powered hospitals: all of the above breakthroughs support the creation of entirely new research and clinical infrastructure for medical care and repair. Creating an AI/robotics-driven preventive and regenerative research hospital is Alex Zhavoronkov’s ultimate goal.

Eleanor Garth

Editor

Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

With a keen interest in all things geroscience, Eleanor covers the biological mechanisms of aging, highlighting how interventions – from nutritional strategies to advanced therapeutics – can influence the aging process at a cellular level. She also investigates the broader implications of aging research, including the integration of longevity science into healthcare strategy and the expanding wellness economy. Her work (hopefully) provides insights into how these developments are shaping the emerging landscape of healthspan optimization and age-related innovation.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Alzheimer’s drug market faces a $14.7bn future

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE